Navigation Links
NovaBay announces third quarter 2007 financial results
Date:11/15/2007

EMERYVILLE, CA, Nov. 15 /PRNewswire-FirstCall/ - NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY), a biopharmaceutical company focused on developing non-antibiotic anti-infective products targeting the treatment or prevention of a wide range of bacterial and viral infections, today reported results for the third quarter ended September 30, 2007.

Net loss for the quarter ended September 30, 2007 was $1.6 million, or $0.24 per share, as compared to a net loss of $1.5 million, or $0.24 per share, for the third quarter of 2006. For the nine months ended September 30, 2007, NovaBay reported a net loss of $4.0 million, or $0.62 per share, as compared to a net loss of $4.2 million, or $0.76 per share, for the nine months ended September 30, 2006.

As of September 30, 2007, NovaBay had $6.9 million in cash, cash equivalents and investments. At September 30, 2007, there were outstanding 6,632,170 shares of common stock and 19,227,195 shares of preferred stock (which were convertible into 9,613,554 shares of common stock).

Recent Developments and Corporate Highlights:

On October 31, 2007, NovaBay completed its initial public offering of

5,000,000 shares of common stock at a price to the public of

$4.00 per share, and received net proceeds of approximately

$17.2 million after deducting underwriting discounts and commissions

of $1.4 million and other offering costs of approximately

$1.4 million. The underwriters have an option to purchase an

additional 750,000 shares of common stock until 30 days after the

closing of the IPO. Upon the closing of the IPO, all shares of

convertible preferred stock outstanding automatically converted into

9,613,554 shares of common stock. As of the closing of the initial

public offering, the Company had 21,254,474 shares of common stock

outstanding and $24.2 million in cash, cash equivalents and

investments.

At the end of September 2007, NovaBay received clearance from the

U.S. Food and Drug Administration (FDA) for its NeutroPhase woundcare

product. NeutroPhase is NovaBay's proprietary solution of

hypochlorous acid, a molecule that is naturally produced by the

body's immune system to protect against pathogens. NeutroPhase has

been cleared by the FDA as a prescription product for moistening

absorbent wound dressings, irrigating and cleaning minor cuts, minor

burns, superficial abrasions and minor irritations of the skin, and

moistening, debriding and irrigating acute and chronic dermal

lesions, such as stage I-IV pressure ulcers, stasis ulcers, leg

ulcers, diabetic foot ulcers, post-surgical wounds, first and second

degree burns, and abrasions and minor irritations of the skin.

NeutroPhase has been licensed to an affiliate of Kinetic Concepts,

Inc. for development and commercialization purposes within the field

of wound healing.

At the end of September 2007, NovaBay completed the treatment phase

of the Phase I safety trial for NVC-422, NovaBay's lead compound in a

class of antimicrobial compounds that it calls the Aganocide

compounds, for the decolonization of the nasal passages prior to

surgery. A total of 96 subjects were enrolled in the trial. NVC-422

is being developed for use prior to surgery to kill pathogens in the

nasal passages, including Methicillin-Resistant Staphylococcus aureus

(MRSA). The presence of MRSA in the nasal passages has been

associated with a significant increase in the risk of surgical

infection and our development program is aimed at reducing this risk.

During the third quarter of 2007, NovaBay initiated toxicology

studies for NVC-422 for the prevention of catheter associated urinary

tract infections, a significant source of hospital-associated

infections. An Investigational New Drug application for this

indication is expected to be filed with the FDA before the end of

2007.

During the third quarter of 2007, NovaBay continued its work to

develop its Aganocide compounds with its partner, an affiliate of

Alcon, Inc., for use in the treatment of infections in the eye, ear

and sinus and in contact lens solutions.

About NovaBay

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus (MRSA). NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus and in contact lens solutions and a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay's NeutroPhase product in woundcare applications.

NovaBay(TM) , Aganocide(TM) and NeutroPhase(TM) are trademarks of NovaBay

Pharmaceuticals, Inc. All other trademarks and trade names are the

property of their respective owners.

Forward Looking Statements

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay's product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

NOVABAY PHARMACEUTICALS, INC.

(a development stage company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2006 2007 2006 2007

------------- ------------- --------------------------

REVENUE

License and

collaboration

revenue $ 208 $ 1,444 $ 208 $ 4,392

------------- ------------- ------------- -------------

Total revenue 208 1,444 208 4,392

EXPENSES

Operating Expenses:

Research and

development 1,122 2,051 2,441 5,580

General and

administrative 634 1,021 2,065 3,125

------------- ------------- ------------- -------------

Total operating

expenses 1,756 3,072 4,506 8,705

Other income, net 58 72 97 307

------------- ------------- ------------- -------------

Net loss $ (1,490) $ (1,556) $ (4,201) $ (4,006)

------------- ------------- ------------- -------------

------------- ------------- ------------- -------------

Basic and diluted

net loss per

share $ (0.24) $ (0.24) $ (0.76) $ (0.62)

Shares used to

compute basic and

diluted net loss

per share 6,234 6,564 5,524 6,494

NOVABAY PHARMACEUTICALS, INC.

(a development stage company)

CONDENSED BALANCE SHEETS

(in thousands)

December 31, September 30,

2006 2007

------------- -------------

(unaudited)

ASSETS

Current assets:

Cash, cash equivalents and investments $ 11,086 $ 6,881

Prepaid expenses and other current assets 226 364

------------- -------------

Total current assets 11,312 7,245

Property and equipment, net 554 912

------------- -------------

TOTAL ASSETS $ 11,866 $ 8,157

------------- -------------

------------- -------------

LIABILITIES AND STOCKHOLDERS' EQUITY

Liabilities:

Current liabilities:

Accounts payable and accrued liabilities $ 886 $ 1,878

Deferred revenue 2,500 3,377

Other current liabilities - 170

------------- -------------

Total current liabilities 3,386 5,425

Deferred revenue - non-current 6,667 4,951

Other non-current liabilities - 373

------------- -------------

Total liabilities 10,053 10,749

------------- -------------

Stockholders' Equity (Deficit):

Convertible preferred stock 192 192

Common stock 63 66

Additional paid-in capital 14,620 14,207

Accumulated other comprehensive income 12 23

Accumulated deficit during development stage (13,074) (17,080)

------------- -------------

Total stockholders' equity (deficit) 1,813 (2,592)

------------- -------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 11,866 $ 8,157

------------- -------------

------------- -------------


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The ... Drug Development through Molecular Imaging.” The focus of ADDMI-IG will be geared towards ... and development pipeline issues. Through ADDMI-IG WMIS will provide a platform for productive ...
(Date:5/25/2016)... Miami, FL (PRWEB) , ... May 25, 2016 , ... ... deep dive into the unique integrative medical wellness offerings of Europe, a continent that ... in Tyrol, Austria will hear from numerous pioneers in medical wellness, including Henri Chenot, ...
(Date:5/25/2016)... ... ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, introduces a ... wellness suites . The two 1,350 sq. ft. suites which debuted in late 2015 ... amenities, from a custom soap selection and in-suite exercise kit to a personal wellness ...
(Date:5/25/2016)... ... May 25, 2016 , ... America Walks , a ... M.S.L., M.S.P.A., of the University of Pittsburgh Graduate School of Public Health , ... Ms. Reichbaum and 24 other advocates from around the country to participate in a ...
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows users to ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... add stylish color grades to their footage. A LUT is a Lookup Table that ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/24/2016)... , May 24, 2016 ... elkaar verbindt, zodat zij collectief patiënten kunnen behandelen, hun ... is het idee achter de nieuwe en revolutionaire MDLinking ... van de Nederlandse vaatchirurg dr. Hans Flu en oncologisch ... app, die inmiddels beschikbaar is, wordt op dinsdag 24 ...
(Date:5/23/2016)... York , May 23, 2016 ... report titled, " Exocrine Pancreatic Insufficiency Market - Global ... - 2023 ." According to the report, the exocrine ... CAGR of 8.3% from 2015 to 2023 to reach ... (EPI) is a condition characterized by the deficiency of ...
Breaking Medicine Technology: